Loading publications…
The last 5 uploaded publications
Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis
Anna Galligan, Amir Iravani, Arian Lasocki, Roslyn Wallace, Alison M. Weppler, Nirupa Sachithanandan, Cherie Chiang, Peter G. Colman, John M. Wentworth, Lavinia Spain, George Au‐Yeung, Belinda Lee, Thomas W. H. Kay, Rodney J. Hicks, Shahneen Sandhu, Balasubramanian Krishnamurthy (2023). Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis. , 14, DOI: https://doi.org/10.3389/fendo.2023.1295865.
Article62 days agoMelanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
Peter K. H. Lau, Breon Feran, Lorey Smith, Arian Lasocki, Ramyar Molania, Kortnye Smith, Alison M. Weppler, Christopher Angel, Damien Kee, Prachi Bhave, Belinda Lee, Richard J. Young, Amir Iravani, Hanxian Aw Yeang, Ismael A. Vergara, David L. Kok, Kate Drummond, Paul J. Neeson, Karen E. Sheppard, Anthony T. Papenfuss, Benjamin Solomon, Shahneen Sandhu, Grant A. McArthur (2021). Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). , 9(10), DOI: https://doi.org/10.1136/jitc-2021-002995.
Article62 days agoFDG PET in the evaluation of immune-related hypophysitis and thyroiditis following combination ipilimumab and nivolumab in advanced melanoma
Amir Iravani, Anna Galligan, Arian Lasocki, Roslyn Wallace, Alison M. Weppler, George Au Yeung, Tim Akhurst, Nirupa Sachithanandan, Cherie Chiang, Shahneen Sandhu, Rodney J. Hicks (2020). FDG PET in the evaluation of immune-related hypophysitis and thyroiditis following combination ipilimumab and nivolumab in advanced melanoma. , 61
Article62 days ago1079MO Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES)
Peter K. H. Lau, Breon Feran, Lorey Smith, Arian Lasocki, Ramyar Molania, Kortnye Smith, Alison M. Weppler, Christopher Angel, Damien Kee, Prachi Bhave, Belinda Lee, Han Xian Aw Yeang, Ismael A. Vergara, David L. Kok, Katharine J. Drummond, Paul J. Neeson, Karen E. Sheppard, Anthony T. Papenfuss, Shahneen Sandhu, Grant A. McArthur (2020). 1079MO Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES). , 31, DOI: https://doi.org/10.1016/j.annonc.2020.08.1203.
Article62 days ago1079MO Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES)
Peter K. H. Lau, Breon Feran, Lorey Smith, Arian Lasocki, Ramyar Molania, Kortnye Smith, Alison M. Weppler, Christopher Angel, Damien Kee, Prachi Bhave, Belinda Lee, Han Xian Aw Yeang, Ismael A. Vergara, David L. Kok, Katharine J. Drummond, Paul J. Neeson, Karen E. Sheppard, Anthony T. Papenfuss, Shahneen Sandhu, Grant A. McArthur (2020). 1079MO Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES). , 31, DOI: https://doi.org/10.1016/j.annonc.2020.08.1203.
Article62 days ago